Phase II drugs that are currently in development for the treatment of cachexia (Q38233278)

31 August 2017

Phase II drugs that are currently in development for the treatment of cachexia (English)

1 reference

31 August 2017

Anne-Marie C Dingemans

1

1 reference

31 August 2017

Judith de Vos-Geelen

2

1 reference

31 August 2017

Ramon Langen

3

1 reference

31 August 2017

Annemie M W Schols

4

1 reference

31 August 2017

language of work or name

English

0 references

publication date

24 July 2014

1 reference

Expert Opinion on Investigational Drugs

31 August 2017

1 reference

31 August 2017

23

1 reference

31 August 2017

12

1 reference

31 August 2017

1655-1669

1 reference

Definition and classification of cancer cachexia: an international consensus

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Cachexia: a new definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Nutrition as a metabolic modulator in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Triggers and mechanisms of skeletal muscle wasting in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Muscle wasting in heart failure: An overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Control of food intake and muscle wasting in cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Protein breakdown in muscle wasting: role of autophagy-lysosome and ubiquitin-proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Cancer cachexia: mediators, signaling, and metabolic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Nuclear transcription factor κ B activation and protein turnover adaptations in skeletal muscle of patients with progressive stages of lung cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Autophagy in locomotor muscles of patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Characterization of a cancer cachectic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

NF-κB activation is required for the transition of pulmonary inflammation to muscle atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

IKKbeta/NF-kappaB activation causes severe muscle wasting in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Brain activity correlated with food preferences: a functional study comparing advanced non-small cell lung cancer patients with and without anorexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Feeding and body-weight regulation by hypothalamic neuropeptides--mediation of the actions of leptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

A systematic review of the evidence on symptom management of cancer-related anorexia and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Systematic review of the treatment of cancer-associated anorexia and weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Exocrine function following the whipple operation as assessed by stool elastase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Placebo controlled trial of enteric coated pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic head region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Systematic review: efficacy and safety of pancreatic enzyme supplements for exocrine pancreatic insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Signalling pathways regulating protein turnover in skeletal muscle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Mechanism of muscle protein degradation in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

The COX-2 pathway regulates growth of atrophied muscle via multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a beta-adrenergic antagonist and a cyclooxygenase-2 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Omega-3 fatty acids and protein metabolism: enhancement of anabolic interventions for sarcopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Oral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non-small cell lung cancer during multimodality treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Influence of eicosapentaenoic acid supplementation on lean body mass in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Effect of anti-inflammatory supplementation with whey peptide and exercise therapy in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Effects of nutritional supplementation combined with low-intensity exercise in malnourished patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Omega-3 fatty acids in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Raised CRP levels mark metabolic and functional impairment in advanced COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Omega 3 Fatty acids and cardiovascular outcomes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

The role of the central ghrelin system in reward from food and chemical drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

EP1572: a novel peptido-mimetic GH secretagogue with potent and selective GH-releasing activity in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Increased mortality associated with growth hormone treatment in critically ill adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

The ACT-ONE trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal c

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Advances in understanding and treating cardiac cachexia: highlights from the 5th Cachexia Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

An antibody blocking activin type II receptors induces strong skeletal muscle hypertrophy and protects from atrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Antibodies to watch in 2014.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Multitargeted treatment of cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Multimodal nutritional rehabilitation improves clinical outcomes of malnourished patients with chronic respiratory failure: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Randomized, placebo-controlled phase III study of docetaxel plus carboplatin with celecoxib and cyclooxygenase-2 expression as a biomarker for patients with advanced non-small-cell lung cancer: the NVALT-4 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Autophagic degradation contributes to muscle wasting in cancer cachexia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

Body composition in patients with non−small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.942729

10.1517/13543784.2014.942729

21 January 2018

Identifiers

DOI

1 reference

release_wmy6arppfvfofch4b3djzsqxda

31 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wmy6arppfvfofch4b3djzsqxda

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference